Two Sigma Investments
ATXS

Two Sigma Investments’s Astria Therapeutics ATXS Stock Holding History

Two Sigma Investments’s Portfolio ATXS Stock Details ATXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-19,428
Closed -$174K – 3197
2024
Q4 		$174K Sell
19,428
-2,042
-10% -$21.7K ﹤0.01% 2894
2024
Q3 		$236K Buy
21,470
+42
+0.2% +$467 ﹤0.01% 2757
2024
Q2 		$195K Buy
21,428
+1,137
+6% +$11.1K ﹤0.01% 2736
2024
Q1 		$286K Sell
20,291
-13,756
-40% -$171K ﹤0.01% 2579
2023
Q4 		$261K Buy
+34,047
New +$188K ﹤0.01% 2740
2023
Q3 		– Sell
-93,913
Closed -$782K – 2951
2023
Q2 		$782K Sell
93,913
-47,107
-33% -$544K ﹤0.01% 2088
2023
Q1 		$1.88M Buy
141,020
+43,967
+45% +$594K 0.01% 1417
2022
Q4 		$1.45M Buy
+97,053
New +$1M ﹤0.01% 1504
2020
Q4 		– Sell
-3,255
Closed -$121K – 3322
2020
Q3 		$121K Sell
3,255
-7,541
-70% -$299K ﹤0.01% 2921
2020
Q2 		$417K Buy
+10,796
New +$385K ﹤0.01% 2136

Other funds holding ATXS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Two Sigma Investments's ATXS Position: Q1 2025 in Review

Two Sigma Investments sold out of Astria Therapeutics (ATXS) in Q1 2025, closing a stake of 19,428 shares — an estimated $174K sold.

Two Sigma Investments first reported a position in ATXS in Q2 2020 and held it in 10 quarters. The position peaked at $1.88M in Q1 2023. 115 funds tracked by Wall St. Rank hold ATXS as of Q1 2025.

  • Two Sigma Investments reported no remaining Astria Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Two Sigma Investments sold 19,428 Astria Therapeutics shares in Q1 2025, an estimated $174K.
  • Two Sigma Investments first reported a position in Astria Therapeutics in Q2 2020 and held it in 10 quarters.
  • Two Sigma Investments's Astria Therapeutics position peaked at $1.88M in Q1 2023.
  • 115 funds tracked by Wall St. Rank held Astria Therapeutics as of Q1 2025.

Based on Two Sigma Investments's 13F filing for Q1 2025, filed 15 May 2025.